L. Abbas, Ume Glaubius, Robert L. Ding, Yajun Hood, Gregory Prevalence of total, acquired and ART-adjusted HIV drug resistance. <p>A: Prevalence of total drug resistance at 2018. B: Prevalence of total drug resistance by 2030. C: Prevalence of acquired drug resistance mutations by 2030. D: Prevalence of acquired drug-resistant mutants by 2030. E: Prevalence of acquired drug-resistant mutants at 2018. F: ART-adjusted drug resistance prevalence at 2018.</p> first-line antiretroviral therapy;Heterosexual HIV epidemic;HIV drug resistance;alternative first-line regimens;M 184V K 65R;modeling study Background Tenofovir-containing regimens;drug resistance levels;tenofovir-containing first-line ART;NNRTI;CD 4-based ART;Considerable HIV drug resistance;IQR;drug resistance;incident infections;K 65R mutations 2019-07-03
    https://plos.figshare.com/articles/figure/Prevalence_of_total_acquired_and_ART-adjusted_HIV_drug_resistance_/8636849
10.1371/journal.pone.0218649.g003